Listata Mini

Quick links to important sections

Listata Mini

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Listata Mini

Understanding Listata Mini

Listata Mini is a medicinal product designed to assist with weight management in adults. It belongs to a class of medications known as gastrointestinal lipase inhibitors. Unlike many weight management aids that act as appetite suppressants or stimulants, this medication functions specifically within the digestive system.

Mechanism of Action

The active component in Listata Mini targets the enzymes responsible for breaking down dietary fats. These enzymes, called lipases, are secreted by the stomach and pancreas. When the medication is present in the digestive tract, it attaches to these enzymes and prevents them from functioning normally.

Under typical circumstances, lipases break down fats into smaller components that the body can absorb through the intestinal lining. By inhibiting these enzymes, Listata Mini ensures that a portion of the fat consumed in meals remains undigested. Because this fat is not broken down, it cannot be absorbed into the bloodstream and is instead eliminated from the body through natural bowel movements.

Role in Weight Management

Listata Mini is utilized as a tool to support weight loss by reducing the net caloric intake from dietary fats. It is intended for use by adults who have a Body Mass Index (BMI) within the overweight or obese range.

The effectiveness of the medication is closely linked to dietary habits. It is designed to be used in conjunction with a reduced-calorie, lower-fat diet. Because the medication only addresses fat absorption and does not affect the metabolism of carbohydrates or proteins, its role is specifically focused on the lipid component of a person's nutritional intake.

What side effects are possible with Listata Mini?

Possible side effects and safety information

The safety profile for Listata Mini (orlistat) is primarily characterized by adverse reactions affecting the Gastrointestinal system, which are directly related to the medicine’s mechanism of action. These effects are classified according to regulatory frequency standards (e.g., EMA/FDA labeling).

Very Common Adverse Reactions (ge 1/10):

The most frequently documented reactions include oily spotting (flatus with discharge), fecal urgency, fatty/oily stool (steatorrhea), oily evacuation, increased defecation, and abdominal pain/discomfort. Systemic effects such as headache are also officially listed as very common. These GI effects are generally described as transient and are more likely to occur early in treatment or when a high-fat diet (more than 30% fat calories) is consumed.

Common Adverse Reactions (ge 1/100 to <1/10):

Common effects include fecal incontinence, nausea, infectious diarrhea, rectal pain/discomfort, vomiting, and urinary tract infection. The regulatory profile also lists common occurrences across other System-Organ Classes, such as anxiety and sleep disorder.

Serious Adverse Reactions and Safety Constraints:

Serious adverse reactions reported during post-marketing surveillance (frequency not known) include severe liver injury (hepatotoxicity), in rare cases leading to hepatic failure, and oxalate nephropathy, which may result in renal failure. Hypersensitivity reactions (e.g., anaphylaxis) and pancreatitis have also been reported.

Safety constraints documented in official labeling note that treatment may impair the absorption of fat-soluble vitamins (A, D, E, and K). Furthermore, the medicine is officially contraindicated during pregnancy and lactation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Listata Mini, or of products containing its active ingredient, requires immediate emergency medical attention due to the documented risk of severe health consequences, particularly severe hepatic injury (liver damage).

Documented Overdose Risks

Official regulatory sources emphasize that the most critical risk is acute liver failure (ALF), which has been reported in post-marketing experience. While the most frequently reported adverse events are often gastrointestinal (such as nausea or vomiting), severe overdose can lead to life-threatening hepatocellular necrosis.

When to Seek Emergency Help

Immediate action is required in all suspected overdose situations. Do not wait for symptoms to appear. The official guidance states to get medical help or contact a Poison Control Center right away.

Overdose Severity and Manifestation Required Emergency Action
Any suspected over-ingestion Contact a Poison Control Center immediately.
Victim has collapsed, had a seizure, has trouble breathing, or can't be awakened Immediately call emergency services (e.g., 911).

The risk of over-ingestion is heightened by the concurrent use of multiple products that may contain the same active ingredient. Treatment should be based on the patient's clinical condition, as determined by medical professionals.

Therapeutic Uses of Listata Mini

What Listata Mini Treats: Main Uses and Benefits

The medication is commonly used to help manage the conditions of obesity and overweight in adults who are generally engaged in a calorie-restricted, low-fat diet. It serves as a tool for patients seeking to achieve weight loss and maintain it over the long term.


Facilitating Weight Reduction and Maintenance

Listata Mini is applied in the treatment of clinically defined excess body weight, particularly when patients require supportive assistance to achieve their goals. The medication may assist with addressing the symptom clusters associated with excess weight and may help achieve weight reduction. The medication is considered relevant for conditions such as obesity and overweight.

Adjunctive Support for Lifestyle Goals

The medication is commonly used to help address the challenge of long-term weight management, assisting patients who have achieved weight loss in sustaining it. It supports patients during this phase of weight regain prevention, which is associated with symptoms that interfere with daily functioning. It is commonly used in clinical scenarios that involve patients actively managing diet.

“This supportive therapeutic approach helps patients cope more steadily with the persistent challenge of weight management, easing the overall symptom load.”

Listata Mini is an adjunctive therapeutic tool that contributes to easing the overall symptom load by supporting the patient’s adherence to a structured eating plan, assisting with maintaining functional stability while managing diet.

Quick Fact: Relief for Weight Challenges
This medication is considered relevant for supporting patients during long-term weight management and addressing symptoms related to weight regain prevention.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Listata Mini?

Eligibility for Listata Mini is defined by regulatory guidelines based on age, weight status, and pre-existing medical conditions. The medicine is formally indicated for Adults (18 years and older) who are overweight, typically defined by a Body Mass Index (BMI) of 28 kg/m^2 or higher, as stated in regulatory labels.


Populations for whom use is Contraindicated

Official regulatory documents state that Listata Mini must not be used by the following groups:

  • Patients with Chronic Malabsorption Syndrome or Cholestasis.
  • Individuals with known Hypersensitivity to the active ingredient orlistat.
  • Women who are pregnant or breast-feeding.
  • Patients taking the immunosuppressant medication Cyclosporine.

Conditional or Restricted Use

Use is not recommended in Children and Adolescents (lt 18 years) as safety and efficacy for the 60 mg dose have not been established. Conditional use, often requiring medical consultation, is advised for patients with Kidney Disease (due to the risk of oxalate nephropathy), Hepatic Impairment, Diabetes, or a history of Eating Disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Listata Mini (orlistat) is primarily based on its potential to reduce the systemic exposure of co-administered substances that require fat for adequate gastrointestinal absorption.

Regulatory documents stipulate that co-administration with acarbose is not recommended/contraindicated due to a lack of data on their combination and the potential for additive GI effects.

Exposure and Timing Restrictions

Interacting Substance Officially Documented Interaction Mandatory Timing Rule
Ciclosporin Reduced plasma levels Administer at least three hours apart
Levothyroxine Reduced absorption and efficacy Administer at least four hours apart
Amiodarone Reduced exposure/absorption Not specified; close monitoring advised
Fat-Soluble Vitamins Reduced absorption (A, D, E, K) Administer multivitamin at least two hours after orlistat or at bedtime

Co-administration with warfarin and other oral anticoagulants is documented to carry a risk of altering coagulation parameters (INR), as the reduction of fat absorption can also decrease Vitamin K absorption. Patients taking antiepileptic drugs must be monitored for potential changes in seizure frequency or severity, as orlistat may reduce the absorption of these medicines. Regulatory labels also document that consuming a diet high in fat (over 30% of total calories) increases the possibility of gastrointestinal adverse reactions.

Mechanism of Action

Listata Mini (orlistat) functions as a covalent inhibitor of gastrointestinal lipases, primarily targeting both gastric lipase and pancreatic lipase within the lumen of the stomach and small intestine. The drug acts by forming a stable covalent bond with a specific serine residue at the catalytic active site of these enzymes.

This molecular interaction renders the lipases inactive, thereby preventing the enzymatic hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. Consequently, the undigested triglycerides remain within the gastrointestinal tract. This inhibition of the digestion cascade results in a systemic reduction in the overall absorption of dietary fat calories, leading to a modulation of overall energy balance. Minimal systemic absorption of the active compound occurs, confirming its localized mechanism of action.

Dosage and Administration Information

How to Use Listata Mini

Listata Mini is an oral capsule medication with a use pattern that is strictly dependent on dietary fat consumption. The medicine is designed to be used as an adjunct to a nutritionally balanced, reduced-calorie, low-fat diet.

Standard Dosing and Administration

The standard regimen for adults is one 60 mg capsule taken three times daily, swallowed whole with water. The maximum daily intake should not exceed three capsules (180 mg).

Administration is timed specifically to meals: the capsule must be taken immediately before, during, or up to one hour after each main meal that contains fat. A key procedural rule for proper use is that the dose must be omitted if a meal is missed or if the meal contains no fat, as the medicine’s action requires the presence of dietary fat.

Treatment Duration and Specific Conditions

Treatment with the 60 mg strength is generally not intended to exceed six months. The continuation of use is conditional: if a loss of at least 5% of initial body weight is not achieved after 12 weeks of continuous use, therapy is discontinued.

To manage potential effects on nutrient absorption, it is standard practice for a multivitamin supplement to be taken daily. This supplement must be taken at a separate time—specifically, at least two hours before or after the Listata Mini capsule, or preferably at bedtime.

Regarding specific populations, the safety and efficacy of the 60 mg strength are not established in persons under 18 years old. No routine dose adjustment is specified for older adults or patients with existing renal or hepatic impairment, due to the drug’s minimal systemic absorption.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Listata Mini

Research examining the use of orlistat (the active ingredient in Listata Mini) for exploring initial weight loss is based primarily on Randomized Controlled Trials (RCTs). These short-term and intermediate-term studies evaluated adults classified as overweight with existing health risks or as obese. Studies focused on outcomes such as the change in body weight and the percentage of participants who achieved a predefined level of weight loss. Findings describe patterns where, on average, the groups using orlistat in combination with a low-calorie diet were associated with differences in measured weight outcomes compared to the groups using the diet alone.

The evidence base for sustaining weight management was evaluated in extended-duration RCTs, with some trials observing responses over time intervals of up to four years. These studies monitored weight regain and reported that a higher percentage of participants in the treated group were monitored as sustaining at least 5% of their initial weight loss compared to those on diet alone.

Orlistat was also studied for its effect on related health factors in populations with co-existing conditions, such as Type 2 diabetes or dyslipidemia. Research examined outcomes such as changes in serum lipids and measures of blood glucose control. Studies report that patients using orlistat were associated with patterns of measured difference in cholesterol markers. In pre-diabetic populations, research explored the incidence of new-onset Type 2 diabetes and reported a pattern of fewer cases compared to groups who only received lifestyle modification.

Research Gaps and Areas of Uncertainty

The body of research, while extensive for initial weight loss, includes areas where long-term outcomes are not well characterized beyond four years. The research setting highlights the requirement for sustained adherence to both the studied treatment regimen and the low-fat diet, which remains a critical factor in the analysis. Data for populations outside of the adult category (such as children or older adults aged ge70) remain limited in the core regulatory evidence.

Key Studies & References

  1. Efficacy of orlistat in type 2 diabetes: a systematic review and meta-analysis
  2. FDA Label: Alli- orlistat capsule (60 mg) - DailyMed

Frequently Asked Questions (FAQ)

Common questions about Listata Mini (FAQ)


Q: How quickly does Listata Mini usually start to work?

The mechanism of Listata Mini, which prevents the absorption of dietary fat in the gut, begins with the very first dose. Official instructions link the continuation of treatment to achieving at least a 5% reduction in initial body weight after 12 weeks of continuous use. This milestone is the measure used in clinical documents to evaluate continued therapy.


Q: Is Listata Mini the same as regular Listata?

Listata Mini is the brand name for the 60 mg capsule strength of the active ingredient, orlistat, which is typically available without a prescription. The same active ingredient, orlistat, is also available in a higher 120 mg capsule strength, which is generally available by prescription. Therefore, the difference lies in the dosage and regulatory status of the formulation.


Q: Why is this version called 'Mini'?

The name 'Mini' reflects that this product contains the 60 mg dose of the active ingredient, orlistat. This dose strength is typically half the dosage of the prescription formulation, which is 120 mg.


Q: Can Listata Mini cause weight changes?

Listata Mini is officially indicated for weight loss and weight maintenance when used as an adjunct to a low-fat diet. The regulatory safety profile does not list unintended weight gain as a common or serious adverse reaction.


Q: Is it normal to feel tired when first starting Listata Mini?

According to official regulatory documents, fatigue and general tiredness or weakness have been documented as common or general adverse events associated with the use of orlistat. It is also noted in official documents that unusual tiredness or weakness may be a symptom that has been associated with rare, serious adverse events like liver injury.


Q: Does Listata Mini affect blood pressure?

Official regulatory labels do not list significant blood pressure changes as a very common or common side effect. Research examining related health factors noted that the weight loss associated with the medicine was linked to patterns of measured difference in certain cardiovascular markers.


Q: Does Listata Mini interact with birth control pills?

While specific oral contraceptives are not listed as a primary interaction, the medicine reduces the absorption of fat-soluble vitamins. Due to the theoretical potential for reduced absorption of other orally administered medications, it is noted that individuals taking oral contraceptives should consult official product information.


Q: How long does the effect of Listata Mini last after taking it?

Listata Mini acts locally by forming a stable bond with digestive enzymes in the gastrointestinal tract, blocking fat absorption from the meal with which it is taken. Because the active compound is minimally absorbed into the bloodstream, its action is localized to the process of fat digestion in the gut during that meal.


Q: Does Listata Mini show up on standard drug tests?

The drug is not classified as a controlled substance by government drug agencies. Furthermore, regulatory documents describe the drug as having minimal systemic absorption into the bloodstream.


Q: How long can a person safely stay on Listata Mini?

Official instructions state that treatment with the 60 mg strength (Listata Mini) is generally not intended to exceed six months. The higher 120 mg strength of the active ingredient is approved for long-term weight management, according to regulatory standards.


Q: Do I need to change my diet while taking Listata Mini?

Yes. Official instructions state that the medicine is designed to be used as an adjunct (an addition) to a nutritionally balanced, reduced-calorie, low-fat diet. Consuming a diet that is too high in fat is documented to increase the possibility of gastrointestinal adverse reactions.


Q: Are there any common long-term effects of taking Listata Mini?

Long-term studies evaluating sustained weight management reported that a higher percentage of participants in the treated group were monitored as sustaining at least 5% of their initial weight loss compared to those on diet alone. The regulatory research base notes that comprehensive long-term safety data beyond four years remains limited.


Q: Can Listata Mini be taken with pain relievers like ibuprofen?

Official regulatory documents do not list a specific direct interaction between orlistat and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.


Q: Is Listata Mini a controlled substance?

No. The drug's active ingredient, orlistat, is not classified as a controlled substance by government drug agencies.


Q: What happens if I forget to take a Listata Mini?

The medicine's action requires the presence of dietary fat. If the capsule is forgotten, the dose should be omitted if it cannot be taken immediately before, during, or up to one hour after a main meal that contains fat. The dose must not be taken later than one hour after the meal.


Q: Is it okay to drink alcohol in moderation while taking Listata Mini?

Clinical study data indicates that the co-administration of orlistat with a moderate amount of alcohol did not result in an alteration of the drug's effects or the systemic exposure to the medicine or the alcohol.


Q: Can I take other cold or flu medications with Listata Mini?

Official documents do not list a specific interaction between orlistat and common ingredients found in cold and flu medications.


Q: Does the time of day matter when taking Listata Mini?

No. The timing of the dose is strictly conditional on the intake of a main meal that contains fat. The capsule must be taken immediately before, during, or up to one hour after the meal, regardless of the time of day.


Q: What are the signs that Listata Mini is beginning to work?

The most common adverse reactions, such as oily spotting and fatty/oily stools, are a direct consequence of the medicine's mechanism and often occur early in treatment. The clearest clinical measure is the achievement of at least 5% loss of initial body weight after 12 weeks, which is required to continue treatment.


Q: Can people with a history of heart problems take Listata Mini?

A history of general heart problems is not listed as a formal contraindication in the regulatory documents. The drug has been studied for its effect on related health factors in populations with co-existing conditions; however, official regulatory documents note that long-term safety on cardiovascular morbidity and mortality has not been established.


Q: Are there different strengths of Listata Mini?

Yes. The active ingredient, orlistat, is generally available in two strengths: the 60 mg capsule (which is Listata Mini) and a 120 mg capsule strength, which is typically available by prescription.


Q: Can men and women take Listata Mini for the same reasons?

The official indications for use, including age and weight status criteria (Body Mass Index), are not based on sex. The only sex-specific contraindications are for women who are pregnant or breast-feeding.


Q: Is Listata Mini habit-forming or addictive?

No. The drug is not classified as a controlled substance by government drug agencies, and it acts locally in the gastrointestinal tract with minimal absorption into the bloodstream. Regulatory information does not suggest that the medicine has a risk of dependence or addiction.


Q: Does Listata Mini interact with caffeine?

Official regulatory documents do not list a specific interaction between orlistat and caffeine.


Q: Does Listata Mini interact with common supplements like Vitamin D?

Yes. Regulatory safety information notes that the medicine may impair the absorption of fat-soluble vitamins, including Vitamin D. Official instructions require patients to take a multivitamin supplement at a separate time—specifically, at least two hours before or after the capsule, or preferably at bedtime.

How should Listata Mini be stored and disposed of?

How to Store and Dispose of Listata Mini

The storage of Listata Mini (orlistat capsules) must adhere to specific regulatory conditions to maintain stability and effectiveness.


Storage Requirements

Condition Requirement
Temperature Store below 25 C (blister packs) or 30 C (glass bottles). Do not freeze.
Protection Keep in a dry place and maintain the container tightly closed to protect from moisture.
Child Safety The medication must be kept out of the sight and reach of children.

Disposal

Unused or expired Listata Mini should be discarded safely after the expiration date. Patients must consult a healthcare professional or pharmacist regarding the proper disposal method for any unused medicine, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Listata Mini found in:

A-Z Index: